INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of argenx SE - ARGX
argenx SE - American Depositary Shares (ARGX)
US:NASDAQ Investor Relations:
investor.argenx.com/phoenix.zhtml?c=254223&p=irol-presentations
Company Research
Source: GlobeNewswire
NEW YORK, Aug. 01, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of argenx SE (“argenx” or the “Company”) (NASDAQ: ARGX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether argenx and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining the class action] On June 30, 2025, the U.S. Food and Drug Administration (“FDA”) issued an alert on a potential signal of serious risks associated with argenx’s Vyvgart Hytrulo product, stating that the treatment has a potential risk of “severe worsening of chronic inflammatory demyelinating polyradiculoneuropathy” based on reports to the FDA Adverse Event Reporting System. The alert also said that the “FDA is evaluating the need for regulatory action.” On this news, argenx’s American Depositary Share (“ADS”) price fe
Show less
Read more
Impact Snapshot
Event Time:
ARGX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ARGX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ARGX alerts
High impacting argenx SE - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
ARGX
News
- argenex (NASDAQ:ARGX) was upgraded by analysts at DZ Bank AG to a "strong-buy" rating.MarketBeat
- argenex (NASDAQ:ARGX) was downgraded by analysts at Baird R W from a "strong-buy" rating to a "hold" rating.MarketBeat
- argenex (NASDAQ:ARGX) had its "neutral" rating reaffirmed by analysts at Robert W. Baird. They now have a $858.00 price target on the stock, down previously from $924.00.MarketBeat
- argenex (NASDAQ:ARGX) had its price target raised by analysts at Royal Bank Of Canada from $860.00 to $925.00. They now have an "outperform" rating on the stock.MarketBeat
- argenx Provides Update on UplighTED Studies of Efgartigimod SC in Thyroid Eye DiseaseGlobeNewswire
ARGX
Earnings
- 10/30/25 - Beat
ARGX
Sec Filings
- 12/17/25 - Form S-8
- 12/15/25 - Form 6-K
- 11/18/25 - Form 6-K
- ARGX's page on the SEC website